BioSpace News Archive

OncoNano Medicine, Inc. today announced the appointment of Elina Lavit as Vice President, Business Development.

Spectrum Solutions , LLC today announced its Chief Scientific Officer, David Vigerust, MS, Ph.D. will be delivering this year’s keynote address in Atlanta, Georgia, at the International Society for Biological and Environmental Repositories (ISBER) annual meeting and conference.

Recordati Rare Diseases Inc. announced today that various scientific abstracts have been accepted and will be featured onsite at the American Association of Clinical Endocrinology (AACE) annual meeting being held in San Diego, California from May 12 – 14, 2022.

Arrakis Therapeutics announced that company management will participate in the following upcoming investor conferences: 2022 RBC Capital Markets Global Healthcare Conference Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a fireside chat on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York.

Cortexyme, Inc. today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

Twist Bioscience Corporation announced that Steffen Hellmold, senior vice president, business development for data storage, will participate in the 2022 Materials Research Society Spring Meeting and Exhibit taking place in Honolulu, Hawai’i May 8-13 and virtually May 23-25.

Thermo Fisher Scientific today launched a new collection of qPCR biopharma offerings to help accelerate drug development to meet a growing demand for novel biologics.

Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announces a presentation at the upcoming Retina World Congress 2022, taking place in Fort Lauderdale, Florida from May 12-15, 2022.

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New Orleans, Louisiana, May 13-16, 2022.

Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty.